C-EQFTAI antibody discovery, bioprinted organoids, immune diversity
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Advance discovery and development of human antibody therapeutics across multiple targets.
Collaboration combining Prellis' organoid and AI platform with Lilly's drug discovery and development capabilities.
Prellis entered a multi-target drug discovery and development collaboration with Lilly.
Assess CD11c-CD21- double-negative extrafollicular memory B cells as biomarkers and potential therapeutic targets in solid tumors including HNSCC and melanoma.
Analysis of circulating and intratumoral memory B cell subsets, antigen-stimulation response, antibody production, differentiation into antibody-secreting cells, tumor localization, and clinical correlations with response and outcomes.
Published study reporting DN3 MBC enrichment and clinical associations in patients with cancer.
DN3 MBCs accumulated in blood and tumors of HNSCC patients, were hyporesponsive to antigen stimulation, had low antibody production, failed to differentiate into antibody-secreting cells, accumulated outside tertiary lymphoid structures, and correlated with poor therapeutic response, advanced disease, and worse outcomes in HNSCC and melanoma.
Assess CD11c-CD21- double-negative memory B cells as biomarkers or therapeutic targets related to poor cancer treatment response and outcomes.
Analysis of circulating and intratumoral DN3 memory B cells in patients with head and neck squamous cell carcinoma and melanoma, including antigen stimulation response, antibody production, localization, and clinical correlations.
Publication reported DN3 MBC enrichment in blood and tumors and correlation with poor therapeutic response, advanced disease, and worse outcomes.
DN3 MBCs were hyporesponsive to antigen stimulation, had low antibody production, failed to differentiate into antibody-secreting cells, accumulated outside tertiary lymphoid structures, and correlated with poor response and outcomes.
Create synthetic lymphoid organs or organoids for antibody design and testing.
Three-dimensional biological material generated using bioprinting or energy-beam-directed formation methods to produce lymphoid organoid structures for antibody-related assays.
European patent application EP4448722A1 was published on 2024-10-23 and listed as pending in the supplied record.
Develop bio-engineered lymphoid organs or organoids for cell-based therapy applications.
Three-dimensional bio-engineered lymphoid organoid systems based on Prellis Biologics patent filings.
WO2023114785A2 was published on 2023-06-22; the supplied record lists the PCT application status as ceased.
Assess extrafollicular CD11c-CD21- double-negative memory B cells as potential biomarkers and therapeutic targets in cancer.
Characterization of circulating and intratumoral DN3 memory B cells in patients with head and neck squamous cell carcinoma and melanoma, including association with therapy response, disease stage, and outcomes.
A 2025 Science Translational Medicine publication reported DN3 memory B cell enrichment in blood and tumors and supported further assessment as biomarkers and therapeutic targets.
DN3 memory B cells accumulated in HNSCC blood and tumors, were hyporesponsive to antigen stimulation, had low antibody production, failed to differentiate into antibody-secreting cells, and correlated with poor therapeutic response, advanced disease, and worse outcomes in HNSCC and melanoma.
Recapture human immune biology in vitro to discover and optimize next-generation fully human antibody therapeutics, including against difficult or high-value targets.
Bioprinted lymph node organoids integrate human immune cell diversity, wet-lab characterization, AI-guided screening, and machine-learning optimization to mine the human antibody repertoire.
Platform described publicly as Prellis' core antibody discovery engine and portfolio basis.
Reported key benefit is higher hit rates on tough targets; no quantitative platform results were supplied.
Discover fully human antibody therapeutics by recapturing human immune biology in vitro and mining human antibody repertoire diversity.
Bioprinted lymph node organoid platform combined with machine learning, wet lab characterization, and AI-guided screening.
Platform described publicly as integrating human biology with machine learning for next-generation therapeutic discovery.
Reported as enabling higher hit rates on tough or high-value targets; no specific program-level efficacy results supplied.
Discover next-generation fully human antibody therapeutics by recapturing human immune biology in 3D-printed organoids and using AI-guided screening and optimization.
3D-printed immune organoids, human immune cell diversity, wet-lab characterization, machine-learning-guided antibody screening and optimization.
Company describes EXIS as its active platform for rapid antibody discovery and portfolio generation.
Develop fully human antibody therapeutics across multiple disease areas using Prellis' human immune biology and AI discovery platform.
Antibody discovery and development using human immune organoids, wet-lab characterization, and AI-guided screening and optimization.
Portfolio publicly described as including fully human antibody therapeutics across multiple disease areas.
Replicate complex human immune-system biology in vitro to generate and screen diverse human antibody responses.
3D bioprinted lymph node organoids used to recapture human immune biology and mine antibody repertoire diversity.
Public site describes LNO platform as the core organoid system for antibody discovery.